KR880011117A - 이미다졸 유도체 및 이의 제조방법 - Google Patents

이미다졸 유도체 및 이의 제조방법 Download PDF

Info

Publication number
KR880011117A
KR880011117A KR1019880002924A KR880002924A KR880011117A KR 880011117 A KR880011117 A KR 880011117A KR 1019880002924 A KR1019880002924 A KR 1019880002924A KR 880002924 A KR880002924 A KR 880002924A KR 880011117 A KR880011117 A KR 880011117A
Authority
KR
South Korea
Prior art keywords
compound
tert
hydroxy
formula
lower alkyl
Prior art date
Application number
KR1019880002924A
Other languages
English (en)
Inventor
클뢰처 빌헬름
몬타본 마르크
뮈스너 레나테
싱게발트 니콜라스
Original Assignee
쟝-쟈크 오게이, 프리돌린 클라우스너
에프.호프만-라 로슈 앤드 캄파니 아크티엔게젤샤프트
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 쟝-쟈크 오게이, 프리돌린 클라우스너, 에프.호프만-라 로슈 앤드 캄파니 아크티엔게젤샤프트 filed Critical 쟝-쟈크 오게이, 프리돌린 클라우스너
Publication of KR880011117A publication Critical patent/KR880011117A/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C07D233/61—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms not forming part of a nitro radical, attached to ring nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/84—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/88—Nitrogen atoms, e.g. allantoin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Epoxy Resins (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

Abstract

내용 없음

Description

이미다졸 유도체 및 이의 제조방법
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (20)

  1. 하기 일반식 (Ⅰ)의 이미다졸 유도체 및 이의 약제학적으로 허용되는 산 부가염.
    상기식에서, R1및 R2는 각각 저급 알킬을 나타내고, X는 -CH(R3)- 또는 -CO- 의 잔기를 나타내며, R3는 수소를 나타내고, R4는 수소 또는 저급 알킬을 나타내거나, R3및 R4가 함께는 추가의 탄소-질소 결합을 나타내며, R5는 수소 또는 저급알킬을 나타내고, R6는 수소, 저급알킬, 저급알킬티오 또는 일반식 -NR7R7의 잔기를 나타내며, R7및 R8은 각각 저급알킬을 나타내거나 질소원자와 함께 5- 또는 6-원 포화 헤테로 사이클을 나타낸다.
  2. 제1항에 있어서, R1및 R2가 각각 메틸을 나타내는 화합물.
  3. 제1항 또는 2항에 있어서, R7가 4-위치에서의 메틸 또는 수소를 나타내는 화합물.
  4. 제1항 내지 3항중 어느 한 항에 있어서, R6가 수소, 메틸, n-프로필, 이소프로필, 메틸머캅토 또는 모르폴리노를 나타내는 화합물.
  5. 제1항 내지 4항중 어느 한 항에 있어서, R3가 수소를 나타내고, R4는 수소 또는 메틸을 나타내거나 R3및 R4가 함께 추가의 탄소-질소 결합을 나타내는 화합물.
  6. 1-(4-하이드록시-3,5-디-3급-부틸벤질아미노)-이미다졸.
  7. 1-(4-하이드록시-3,5-디-3급-부틸벤질리덴아미노)-2-메틸이미다졸.
  8. 1-(4-하이드록시-3,5-디-3급-부틸벤질리덴아미노)-이미다졸.
  9. 1-(4-하이드록시-3,5-디-3급-부틸벤질아미노)-2-메틸이미다졸.
  10. 1-(4-하이드록시-3,5-디-3급-부틸벤질아미노)-2-프로필이미다졸.
  11. 1-(4-하이드록시-3,5-디-3급-부틸벤질아미노)-2-메틸머캅토이미다졸.
  12. 1-(4-하이드록시-3,5-디-3급-부틸벤조일아미노)-2-메틸이미다졸 : 1-(4-하이드록시-3,5-디-3급-부틸벤조일아미노)이미다졸 : 1-(4-하이드록시-3,5-디-3급-부틸벤질리덴아미노)-2-모르폴리노이미다졸 : 1-(4-하이드록시-3,5-디-3급-부틸벤질아미노)-2-모르폴리노이미다졸 : 1-(4-하이드록시-3,5-디-3급-부틸벤질리덴아미노)-2-이소프로필이미다졸 : 1-(4-하이드록시-3,5-디-3급-부틸벤질리덴아미노)-4-메틸이미다졸 : 1-(4-하이드록시-3,5-디-3급-부틸벤질아미노)-4-메틸이미다졸 : 1-(4-하이드록시-3,5-디-3급-부틸벤질리덴아미노)-2-프로필이미다졸 : 및 1-[-(4-하이드록실-3,5-디-3급-부틸벤질)-N-메틸아미노]이미다졸.
  13. 치료학적 활성 물질로서 사용하기 위한 제1항 내지 12항중 어느 한 항의 화합물.
  14. 염증-억제 및 부종-억제 활성 물질로서 사용하기 위한 제1항 내지 12항중 어느 한 항의 화합물.
  15. (a) 일반식 (Ⅱ) 화합물을 일반식 (Ⅲ)의 알데하이드와 축합반응시키거나, (b) 일반식(Ⅳ)의 화합물을 일반식 (Ⅴ)의 카복실산의 반응성 유도체로 아실화 시키거나, (c) 일반식 (Ⅰa) 화합물을 환원시키거나, (d) 일반식 (Ⅰb)의 화합물을 환원시키거나, (e) 일반식 (Ⅰc) 화합물을 N-알킬화시키거나, (f) 일반식 (Ⅰc) 화합물을 탈수소화시키거나, (g) 일반식 (Ⅰd) 화합물로부터 알킬티오 그룹을 제거시키거나, (h) 일반식 (Ⅰ) 화합물을 약제학적으로 허용되는 산부가염으로 전환시킴을 포함하여, 제1항 내지 12항중 어느 한 항의 화합물을 제조하는 방법.
    상기식에서, R1및 R2는 각각 저급 알킬을 나타내고, X는 -CH(R3)- 또는 -CO-의 잔기를 나타내며, R3는 수소를 나타내고, R4는 수소 또는 저급알킬을 나타내거나, R3및 R4가 함께는 추가의 탄소-질소 결합을 나타내며, R5는 수소 또는 저급알킬을 나타내고, R6는 수소, 저급알킬, 저급알킬티오 또는 일반식 -NR7R8의 잔기를 나타내며, R7및 R8은 각각 저급알킬을 나타내거나 질소원자와 함께 5- 또는 6-원 포화 헤테로사이클을 나타내고, R4'는 수소 또는 저급알킬을 나타내며, X'는 메틸렌 또는 카보닐그룹을 나타내고, R6'는 저급알킬티오를 나타낸다.
  16. 제1항 내지 12항중 어느 한 항에 따른 화합물 및 치료학적으로 불활성인 부형제를 함유하는 약제.
  17. 제1항 내지 12항중 어느 한 항이 따른 화합물 및 치료학적으로 불활성일 부형제를 함유하는 염증-억제 및 부종-억제용 약제.
  18. 질병, 특히 염증 및 부종을 억제하거나 예방하는데 있어서, 또는 염증 및 부종치료용 억제의 제조를 위한, 제1항 내지 12항중 어느 한 항에 따른 화합물의 용도.
  19. 제1항 내지 12항중 어느 한 항에 있어서, 각각 제15항의 방법 또는 이의 화학적 유사방법에 의해 제조된 화합물.
  20. 본 명세서에 기술된 바와 같은 발명.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019880002924A 1987-03-20 1988-03-19 이미다졸 유도체 및 이의 제조방법 KR880011117A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CH107387 1987-03-20
CH1073/87-9 1987-03-20

Publications (1)

Publication Number Publication Date
KR880011117A true KR880011117A (ko) 1988-10-26

Family

ID=4201822

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019880002924A KR880011117A (ko) 1987-03-20 1988-03-19 이미다졸 유도체 및 이의 제조방법

Country Status (23)

Country Link
US (1) US4908363A (ko)
EP (1) EP0283857B1 (ko)
JP (1) JPS63253070A (ko)
KR (1) KR880011117A (ko)
CN (1) CN1016169B (ko)
AT (1) ATE73777T1 (ko)
AU (1) AU613349B2 (ko)
CS (1) CS276093B6 (ko)
DE (1) DE3869163D1 (ko)
DK (1) DK59888A (ko)
ES (1) ES2032482T3 (ko)
FI (1) FI880813A (ko)
GR (1) GR3004729T3 (ko)
HU (1) HU201312B (ko)
IL (1) IL85725A (ko)
MC (1) MC1919A1 (ko)
MX (1) MX10721A (ko)
NO (1) NO170215C (ko)
NZ (1) NZ223862A (ko)
PT (1) PT87025B (ko)
SU (1) SU1657057A3 (ko)
YU (1) YU46444B (ko)
ZA (1) ZA881810B (ko)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5073566A (en) * 1989-11-30 1991-12-17 Eli Lilly And Company Angiotensin ii antagonist 1,3-imidazoles and use thereas
US5401851A (en) * 1992-06-03 1995-03-28 Eli Lilly And Company Angiotensin II antagonists
US5612360A (en) * 1992-06-03 1997-03-18 Eli Lilly And Company Angiotensin II antagonists
US5574057A (en) * 1993-02-03 1996-11-12 University Of Utah Research Foundation Naamidine A extracted from sea sponges and methods for its use as an anti-tumor agent
US5523310A (en) * 1994-12-05 1996-06-04 Hoffmann-La Roche Inc. 1,2,3-triazole derivatives
AU1383200A (en) 1998-11-23 2000-06-13 F. Hoffmann-La Roche Ag Synthesis of anti-inflammatory (1,2,3)triazoles
DE10132896A1 (de) * 2001-07-06 2003-01-16 Bayer Cropscience Ag Heterocyclische Amidderivate
WO2003010143A1 (en) 2001-07-26 2003-02-06 Samsung Electronics Co., Ltd. Dialkylhydroxybenzoic acid derivatives containing metal chelating groups and their therapeutic uses
EP1431292A1 (en) * 2002-12-16 2004-06-23 Laboratoire Theramex 1-N-phenylamino-1H-imidazole derivatives as aromatase inhibitors

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS57501238A (ko) * 1980-07-31 1982-07-15
DE3674054D1 (de) * 1985-04-26 1990-10-18 Hoffmann La Roche 1,3-disubstituierte imidazoliumsalze.
ZW6687A1 (en) * 1986-05-13 1987-12-02 Hoffmann La Roche 1,3-disubstituted imidazolium salts
MW7087A1 (en) * 1986-10-03 1988-05-11 Hoffmann La Roche 1,3-disubstituted imidazolium salts
WO1988007040A1 (en) * 1987-03-20 1988-09-22 E.I. Du Pont De Nemours And Company Fungicidal aminotriazoles and aminoimidazoles

Also Published As

Publication number Publication date
EP0283857B1 (de) 1992-03-18
DK59888A (da) 1988-09-21
FI880813A (fi) 1988-09-21
CN1016169B (zh) 1992-04-08
IL85725A0 (en) 1988-08-31
AU613349B2 (en) 1991-08-01
AU1353288A (en) 1988-09-22
YU40388A (en) 1990-02-28
GR3004729T3 (ko) 1993-04-28
PT87025B (pt) 1992-06-30
NO170215C (no) 1992-09-23
MX10721A (es) 1993-09-01
YU46444B (sh) 1993-10-20
CS276093B6 (en) 1992-04-15
CN88101452A (zh) 1988-10-05
FI880813A0 (fi) 1988-02-22
NO881199L (no) 1988-09-21
CS8800891A2 (en) 1990-09-12
SU1657057A3 (ru) 1991-06-15
HU201312B (en) 1990-10-28
HUT49581A (en) 1989-10-30
IL85725A (en) 1991-12-12
NZ223862A (en) 1990-08-28
PT87025A (pt) 1988-04-01
MC1919A1 (fr) 1989-04-06
JPS63253070A (ja) 1988-10-20
DE3869163D1 (de) 1992-04-23
DK59888D0 (da) 1988-02-05
NO170215B (no) 1992-06-15
EP0283857A1 (de) 1988-09-28
NO881199D0 (no) 1988-03-18
ZA881810B (en) 1988-09-20
US4908363A (en) 1990-03-13
ATE73777T1 (de) 1992-04-15
ES2032482T3 (es) 1993-02-16

Similar Documents

Publication Publication Date Title
ATE126216T1 (de) Pyrazolderivate, verfahren zu deren herstellung und diese enthaltende pharmazeutische zusammenstellung.
ES8603408A1 (es) Un procedimiento para la preparacion de un compuesto de 2-oxindol-1-carboxamida
WO2000021927A3 (en) Pyrrole-2,5-diones as gsk-3 inhibitors
DE69230163T2 (de) Thiazolylbenzofuranderivate, Verfahren zu deren Herstellung und pharmazeutische Zusammensetzungen, die sie enthalten
ATE109149T1 (de) 3-pyrrolidinylthio-1-azabicyclo(3.2.0>-hept-2-e - 2-carbonsäureverbindungen.
LU91362I2 (fr) Palipéridone et ses dérivés pharmaceutiquement acceptables (INVEGA)
KR840000568A (ko) 두고리 피리미딘-5-온 유도체의 제조방법
KR960706482A (ko) 4,5-디아릴옥사졸 유도체(4,5-diaryloxazole derivatives)
ATE132150T1 (de) 3-alkenyl-1-azabicyclo(3.2.0)hept-2-en-2- carbonsäure-verbindungen
ATE107306T1 (de) 3-pyrrolidinylthio-1-azabicyclo (3.2.0)hept-2-en- 2-carbonsäure-verbindungen.
KR890001547A (ko) 2-(헤테로사이클릴알킬)이미다졸피리딘
KR930701415A (ko) 약학적으로 활성인 벤조퀴나졸린 화합물
KR880011117A (ko) 이미다졸 유도체 및 이의 제조방법
KR910019975A (ko) 인돌 유도체
DK0538192T3 (da) Hidtil ukendte 17beta-substituerede aza-androstan-derivater
ES8800142A1 (es) Un procedimiento para preparar un derivado de semicarbazida
ES2103161A1 (es) Derivados de cicloheptimidazol, metodo de fabricacion de los mismos y agentes terapeuticos que contienen estos compuestos.
DK0835251T3 (da) Fremgangsmåde til fremstilling af liponsyre
KR930702354A (ko) 피롤로아제핀 유도체
DE3685942T2 (de) 2-pyridylessigsaeurederivate, verfahren zu ihrer herstellung und sie enthaltende pharmazeutische zusammensetzungen.
KR900004721A (ko) 항고혈압성 3-피페리디닐-인다졸 유도체
KR960705778A (ko) 2-옥소인돌린 유도체(2-Oxoindoline Derivative)

Legal Events

Date Code Title Description
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid